SecBot SecBot
8-K ·Filed Jun 29, 2026

RGNX

REGENXBIO Inc.
BULLISH
Impact 7/10
Horizonweeks Processed4mo ago SEC0001193125-26-286825
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

The $100M milestone adds substantial near-term cash for a sub-$700M market cap company, reducing financing risk. Key catalysts ahead: ASRS data in July and pivotal ATMOSPHERE/ASCENT topline data in Q4 2026. Monitor for sustained momentum on sura-vec across diabetic retinopathy and wet AMD indications.

DirectionBullish
Confidencehigh
Horizonweeks

surabgene lomparvovec

▲ Bullish Named in this 8-K
Impact
Phase
Phase 3
Time to market
If positive Phase 3 data in Q4 2026, regulatory filing likely 2027 with potential FDA approval 2028 for wet AMD (subretinal). Diabetic retinopathy program (NAAVIGATE) is Phase IIb/III and further out.
Next catalyst
None dated

What to watchWatch for topline Phase 3 data from ATMOSPHERE/ASCENT in Q4 2026, this is the single biggest binary event for RGNX. Interim ALTITUDE data at ASRS July 2026 provides a near-term sentiment check. The $100M AbbVie milestone extends cash runway into late 2027, reducing near-term dilution risk.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$11.83
T+0 close · Jun 29, 2026 · via day close
Latest settled
−31.11%
T+60 · $8.15
Vs SPY
−35.49%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 29 $11.83entry
  2. T+1 · 5mo ago +1.27%α +0.49% · $11.98
  3. T+5 · 4mo ago +25.36%α +23.97% · $14.83
  4. T+20 · 4mo ago −17.75%α −17.47% · $9.73
  5. T+60 · 8w ago −31.11%α −35.49% · $8.15
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

REGENXBIO announced the first patient dosing in the Phase IIb/III NAAVIGATE trial of surabgene lomparvovec (sura-vec) in diabetic retinopathy using suprachoroidal delivery. This triggered a $100 million milestone payment from AbbVie, expected in July 2026. The event de-risks the program's regulatory path and provides a significant non-dilutive cash infusion for a company with a $677 million market cap.

Key Facts

  • First patient dosed in Phase IIb/III NAAVIGATE trial of surabgene lomparvovec in diabetic retinopathy (suprachoroidal delivery)
  • $100 million milestone payment earned from AbbVie, expected in July 2026
  • NAAVIGATE trial to enroll approximately 135 participants in the US; primary endpoint is >2-step DRSS improvement at one year
  • Two-and-a-half year data from ALTITUDE trial and five-year data from Phase I/IIa subretinal wet AMD study to be presented at ASRS July 2026
  • Topline data from ATMOSPHERE and ASCENT pivotal trials of subretinal sura-vec in wet AMD expected in Q4 2026

Financial Impact

$100 million near-term cash milestone from AbbVie, representing ~15% of current market cap

cashcash_flowscollaboration_revenue

Risk Factors

  • Phase IIb/III trial may fail to meet primary endpoint of >2-step DRSS improvement
  • Competition from existing anti-VEGF therapies and emerging gene therapies for retinal diseases
  • Dependence on AbbVie partnership for commercialization and further milestones

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
89% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-286825
Document: 0001193125-26-286825-index.html0001193125-26-286825
Document: 0001193125-26-286825.txt0001193125-26-286825

Track record

15 reports on RGNX

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +29.65% at T+60 after the Jul 20, 2026 report. 2 of 5 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.69 Now $7.32 −4.81% settles Feb 8
  2. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $7.38 Now $7.32 +0.81% settles Feb 3
  3. Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $7.71 Now $7.32 −5.06% settles Feb 2
  4. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.93 Now $7.32 +5.70% settles Jan 13
  5. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $7.26 Now $7.32 +0.83% settles Jan 8
  6. Aug 27, 202611w ago Insider Buy Bullish 5/10 Entry $9.66 Now $7.32 −24.22% settles Nov 23
  7. Aug 25, 202611w ago 8-K Neutral 3/10 Entry $9.38 Now $7.32 −21.96% settles Nov 19
  8. Aug 6, 202614w ago 8-K Bullish 7/10 Entry $11.28 to $7.41 Now $7.32 −35.11% ▼ −34.31% −32.88% vs SPY
  9. Aug 3, 202615w ago Press Release Neutral 1/10 Entry $9.96 to $6.59 Now $7.32 −26.51% ▼ −33.84% −35.62% vs SPY
  10. Jul 20, 202617w ago 8-K Bearish 6/10 Entry $10.32 to $7.26 Now $7.32 +29.07% ▲ +29.65% +34.49% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026